PharmacovigilanceOfficial

EMA publishes 2026 pharmacovigilance recommendations for centrally authorised veterinary medicines

🇪🇺 EMA · Mon 09 Nov 2026

The European Medicines Agency has released a document setting out pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2026.

The European Medicines Agency (EMA) published a document on 9 November 2026 titled "Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2026".

The full text of the publication was not available when this article was prepared. Which products, active substances or safety topics the recommendations cover, and what actions they set out, cannot be reported here.

As context, centrally authorised veterinary medicines are those approved through the EU-wide procedure, in which the EMA's veterinary medicines committee (CVMP) gives an opinion and the European Commission grants the marketing authorisation. Safety monitoring of these products is a continuing duty for marketing authorisation holders and regulators.

What it means for your team

  • Veterinary pharmacovigilance teams should read the full EMA document to see whether any of their centrally authorised products are named.
  • Regulatory affairs teams should check whether the recommendations imply product information updates or other follow-up for their portfolios.
  • Until the detail is confirmed, no assumptions should be made about the scope or content of the recommendations.

Official source: EMA ↗

Article written by VigiEye from the official source (EMA). AI-assisted; check the source before acting.

More Pharmacovigilance All →